Sort   by:  
 Page size 
0
UnknownCytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.
Not available
S-EPMC7911972 | biostudies-literature
0
UnknownSyngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.
Not available
S-EPMC4910707 | biostudies-literature
0
UnknownAdenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Not available
S-EPMC6127851 | biostudies-literature
0
UnknownTNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.
Not available
S-EPMC5927535 | biostudies-literature
0
UnknownOncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.
Not available
S-EPMC4801445 | biostudies-literature
0
UnknownAdenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Not available
S-EPMC5023385 | biostudies-literature
0
UnknownAbscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
Not available
S-EPMC6288321 | biostudies-literature
0
UnknownOncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
Not available
S-EPMC5363700 | biostudies-literature
0
UnknownCD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.
Not available
S-EPMC6207416 | biostudies-literature
0
UnknownPancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Not available
S-EPMC5928866 | biostudies-literature
Sort   by:  
 Page size